Related Experiment Video
Updated: Jun 18, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
Tachycardia-mediated cardiomyopathy: recognition and management
Rakesh Gopinathannair1, Renee Sullivan, Brian Olshansky
1University of Iowa Hospitals, 200 Hawkins Drive, 4426a JCP, Iowa City, IA 52242, USA.
Insights
Persistent tachycardia can cause heart dysfunction, known as tachycardia-mediated cardiomyopathy. Early management can improve heart function, but lasting cellular changes may increase sudden death risk.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure
Background:
- Tachycardia-mediated cardiomyopathy (TMC) results from persistent rapid heart rhythms causing ventricular dysfunction.
- Cellular and extracellular changes develop over time, potentially leading to significant heart muscle impairment.
Purpose of the Study:
- To review the etiology, pathophysiology, and clinical manifestations of TMC.
- To discuss current and future management strategies for TMC, focusing on prevention and early recognition.
Main Methods:
- Literature review of studies on tachycardia-mediated cardiomyopathy.
- Analysis of cellular mechanisms and clinical outcomes related to sustained tachycardia.
Main Results:
- Pharmacologic and procedural interventions can lead to rapid symptom recovery and improved ejection fraction.
- Persistent ultrastructural changes remain a concern, potentially causing rapid functional decline or sudden death, even after normalization of ejection fraction.
Conclusions:
- While TMC is increasingly understood, ongoing research is crucial for prevention and optimal acute and long-term management.
- Effective management aims to reduce heart failure incidence and mitigate the risk of sudden cardiac death in affected individuals.
Abstract:
Tachycardia-mediated cardiomyopathy is a cause of ventricular dysfunction due to, at least partially, persistent tachycardia leading to cellular and extracellular perturbations. Cardiomyopathy may take years to develop, but pharmacologic management to achieve rate control and reverse remodeling, as well as cardioversion or ablative strategies to stop the tachycardia, can result in rapid recovery from symptoms and gradual improvement in left ventricular ejection fraction. However, ultrastructural changes can remain and may lead to a rapid decline in ventricular function if tachycardia recurs. Ultrastructural changes may also explain a propensity toward sudden death even if the ejection fraction normalizes. Although the etiology, pathophysiology, and late clinical manifestations of tachycardia-mediated cardiomyopathy are beginning to be understood, investigation continues, focusing on prevention, early recognition, and acute and long-term management in an attempt to lessen heart failure and prevent risk of sudden death.
More Related Videos
09:36Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Related Concept Videos
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy